A new trading day began on Monday, with Janux Therapeutics Inc (NASDAQ: JANX) stock price down -5.17% from the previous day of trading, before settling in for the closing price of $24.0. JANX’s price has ranged from $21.73 to $71.71 over the past 52 weeks.
Annual sales at Healthcare sector company slipped by -67.90% over the past five years. Meanwhile, its annual earnings per share averaged -76.83%. With a float of $54.31 million, this company’s outstanding shares have now reached $59.30 million.
Janux Therapeutics Inc (JANX) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Janux Therapeutics Inc is 9.62%, while institutional ownership is 106.15%. The most recent insider transaction that took place on May 01 ’25, was worth 106,745. In this transaction Chief Business Officer of this company sold 3,333 shares at a rate of $32.03, taking the stock ownership to the 82,139 shares. Before that another transaction happened on May 01 ’25, when Company’s Officer proposed sale 3,333 for $33.20, making the entire transaction worth $110,656.
Janux Therapeutics Inc (JANX) Performance Highlights and Predictions
In its latest quarterly report, released on 9/30/2024, the company reported earnings of -0.51 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.71 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -76.83% per share during the next fiscal year.
Janux Therapeutics Inc (NASDAQ: JANX) Trading Performance Indicators
Here are Janux Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 47.03. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3108.49.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.80, a number that is poised to hit -0.61 in the next quarter and is forecasted to reach -3.01 in one year’s time.
Technical Analysis of Janux Therapeutics Inc (JANX)
Janux Therapeutics Inc (NASDAQ: JANX) saw its 5-day average volume 0.85 million, a negative change from its year-to-date volume of 0.9 million. As of the previous 9 days, the stock’s Stochastic %D was 44.94%.
During the past 100 days, Janux Therapeutics Inc’s (JANX) raw stochastic average was set at 15.47%, which indicates a significant decrease from 28.45% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.26 in the past 14 days, which was lower than the 1.35 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $23.84, while its 200-day Moving Average is $30.52. Nevertheless, the first resistance level for the watch stands at $23.93 in the near term. At $25.11, the stock is likely to face the second major resistance level. The third major resistance level sits at $25.72. If the price goes on to break the first support level at $22.14, it is likely to go to the next support level at $21.53. Assuming the price breaks the second support level, the third support level stands at $20.35.
Janux Therapeutics Inc (NASDAQ: JANX) Key Stats
With a market capitalization of 1.37 billion, the company has a total of 60,094K Shares Outstanding. Currently, annual sales are 10,590 K while annual income is -68,990 K. The company’s previous quarter sales were 0 K while its latest quarter income was -33,860 K.
